Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Preferred Stock Liabilities (2023 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 3 years of Preferred Stock Liabilities data on record, last reported at $46.1 million in Q2 2025.

  • For Q2 2025, Preferred Stock Liabilities rose 8.24% year-over-year to $46.1 million; the TTM value through May 2025 reached $46.1 million, up 8.24%, while the annual FY2025 figure was $46.1 million, 8.24% up from the prior year.
  • Preferred Stock Liabilities reached $46.1 million in Q2 2025 per LFCR's latest filing, up from $45.2 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $46.1 million in Q2 2025 and bottomed at $38.5 million in Q1 2023.
  • Average Preferred Stock Liabilities over 3 years is $42.2 million, with a median of $42.2 million recorded in 2024.
  • Peak YoY movement for Preferred Stock Liabilities: rose 8.41% in 2024, then rose 8.24% in 2025.
  • A 3-year view of Preferred Stock Liabilities shows it stood at $40.9 million in 2023, then increased by 8.28% to $44.3 million in 2024, then rose by 4.03% to $46.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Preferred Stock Liabilities were $46.1 million in Q2 2025, $45.2 million in Q1 2025, and $44.3 million in Q4 2024.